Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P.

Clin Cancer Res. 2019 Apr 19. doi: 10.1158/1078-0432.CCR-18-3275. [Epub ahead of print]

PMID:
31004002
2.

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.

Klener P, Salek D, Pytlik R, Mocikova H, Forsterova K, Blahovcova P, Campr V, Prochazka V, Obr A, Jaksa R, Kuntscherova J, Boudová L, Kodet R, Janikova A, Trneny M.

Am J Hematol. 2019 Feb;94(2):E50-E53. doi: 10.1002/ajh.25362. Epub 2018 Dec 13. No abstract available.

PMID:
30474171
3.

Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.

Klener P, Fronkova E, Kalinova M, Belada D, Forsterova K, Pytlik R, Blahovcova P, Simkovic M, Salek D, Mocikova H, Prochazka V, Janikova A, Vaskova M, Mejstrikova E, Kodet R, Trka J, Trneny M.

Hematol Oncol. 2018 Dec;36(5):773-778. doi: 10.1002/hon.2550. Epub 2018 Sep 13.

PMID:
30129045
4.

Cyclin D1 mRNA as a molecular marker for minimal residual disease monitoring in patients with mantle cell lymphoma.

Lokvenc M, Kalinova M, Forsterova K, Klener P, Trneny M, Fronkova E, Kodet R.

Ann Hematol. 2018 Mar;97(3):467-474. doi: 10.1007/s00277-017-3210-8. Epub 2017 Dec 22.

PMID:
29273915
5.

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

Klener P, Fronkova E, Belada D, Forsterova K, Pytlik R, Kalinova M, Simkovic M, Salek D, Mocikova H, Prochazka V, Blahovcova P, Janikova A, Markova J, Obr A, Berkova A, Kubinyi J, Vaskova M, Mejstrikova E, Campr V, Jaksa R, Kodet R, Michalova K, Trka J, Trneny M.

Hematol Oncol. 2018 Feb;36(1):110-115. doi: 10.1002/hon.2483. Epub 2017 Oct 30.

PMID:
29083050
6.

Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.

Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, Soukup J, Kulvait V, Vargova J, Fiser K, Prukova D, Alam M, Calvin Lenyeletse Maswabi B, Michalova K, Zemanova Z, Jancuskova T, Pekova S, Trneny M.

Int J Cancer. 2016 Nov 15;139(10):2252-60. doi: 10.1002/ijc.30263. Epub 2016 Aug 2.

7.

The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma.

Kalinova M, Fronkova E, Klener P, Forsterova K, Lokvenc M, Mejstrikova E, Belada D, Mocikova H, Trneny M, Kodet R, Trka J.

Br J Haematol. 2015 Apr;169(1):145-8. doi: 10.1111/bjh.13182. Epub 2014 Oct 14. No abstract available.

PMID:
25312883
8.

Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics.

Racil Z, Toskova M, Kocmanova I, Buresova L, Kouba M, Drgona L, Masarova L, Guman T, Tothova E, Gabzdilova J, Forsterova K, Haber J, Ziakova B, Bojtarova E, Rolencova M, Timilsina S, Cetkovsky P, Mayer J.

Leuk Lymphoma. 2013 May;54(5):1042-7. doi: 10.3109/10428194.2012.729057. Epub 2012 Nov 15.

PMID:
23088794
9.

Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005-2009.

Racil Z, Weinbergerova B, Kocmanova I, Muzik J, Kouba M, Drgona L, Masarova L, Guman T, Tothova E, Forsterova K, Haber J, Ziakova B, Bojtarova E, Vydra J, Mudry P, Foralova R, Sejnova D, Mallatova N, Kandrnal V, Cetkovsky P, Mayer J.

Int J Infect Dis. 2013 Feb;17(2):e101-9. doi: 10.1016/j.ijid.2012.09.004. Epub 2012 Oct 22.

10.

The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.

Benesova K, Forsterova K, Votavova H, Campr V, Stritesky J, Velenska Z, Prochazka B, Pytlik R, Trneny M.

Neoplasma. 2013;60(1):68-73. doi: 10.4149/neo_2013_010.

PMID:
23067219
11.

Advanced rai stage in patients with chronic lymphocytic leukaemia correlates with simultaneous hypermethylation of plural tumour suppressor genes.

Forsterová K, Votavová H, Schwarz J, Karban J, Stuka C, Trněný M.

Folia Biol (Praha). 2010;56(4):158-64.

12.

Distinguishing of primary mediastinal B-cell lymphoma and diffuse large B-cell lymphoma using real-time quantitative polymerase chain reaction.

Votavova H, Forsterova K, Campr V, Sritesky J, Velenska Z, Pytlik R, Kubackova K, Prochazka B, Kodet R, Spicka I, Krejcova H, Trneny M, Klener P.

Neoplasma. 2010;57(5):449-54.

PMID:
20568899
13.

Optimized protocol for gene expression analysis in formalin-fixed, paraffin-embedded tissue using real-time quantitative polymerase chain reaction.

Votavova H, Forsterova K, Stritesky J, Velenska Z, Trneny M.

Diagn Mol Pathol. 2009 Sep;18(3):176-82. doi: 10.1097/PDM.0b013e31818d1091.

PMID:
19704263
14.

Oxidation of an antitumor drug ellipticine by peroxidases.

Poljaková J, Forsterová K, Sulc M, Frei E, Stiborová M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005 Dec;149(2):449-53.

15.

The use of comparative duplex PCR in monitoring of patients with non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Slavícková A, Forsterová K, Ivánek R, Cerný J, Klener P.

Folia Biol (Praha). 2005;51(6):177-9.

16.

The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.

Stiborová M, Sejbal J, Borek-Dohalská L, Aimová D, Poljaková J, Forsterová K, Rupertová M, Wiesner J, Hudecek J, Wiessler M, Frei E.

Cancer Res. 2004 Nov 15;64(22):8374-80.

Supplemental Content

Loading ...
Support Center